Daiichi Sankyo (DSNKY) Expected to Release Earnings on Friday

Daiichi Sankyo (OTCMKTS:DSNKY) is expected to post its resultson Friday, July 31st. Analysts expect Daiichi Sankyo to post earnings of $0.2608 per share and revenue of $3.3434 billion for the quarter. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. On average, analysts expect Daiichi Sankyo to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Daiichi Sankyo Price Performance

Shares of OTCMKTS:DSNKY opened at $17.01 on Friday. The firm has a market capitalization of $31.69 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 2.97 and a beta of -0.17. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The business’s 50 day simple moving average is $16.40 and its 200-day simple moving average is $17.91. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.